Sanofi (NYSE:SNY) will be posting its quarterly earnings results before the market opens on Thursday, November 2nd. Analysts expect Sanofi to post earnings of $0.96 per share for the quarter.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company’s revenue was down 2.3% on a year-over-year basis. On average, analysts expect Sanofi to post $3.32 EPS for the current fiscal year and $3.47 EPS for the next fiscal year.

Sanofi (SNY) opened at 47.67 on Thursday. Sanofi has a 12 month low of $37.25 and a 12 month high of $50.65. The firm has a market cap of $119.72 billion, a PE ratio of 11.07 and a beta of 0.87. The stock’s 50 day moving average is $49.49 and its 200 day moving average is $48.40.

TRADEMARK VIOLATION WARNING: “Sanofi (SNY) to Release Earnings on Thursday” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/26/sanofi-sny-to-release-earnings-on-thursday.html.

A number of analysts have issued reports on the company. Cowen and Company reissued a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Finally, HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $53.50.

In other news, major shareholder Sanofi acquired 105,820 shares of Sanofi stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.00% of the company’s stock.

An institutional investor recently raised its position in Sanofi stock. State Street Corp grew its position in Sanofi (NYSE:SNY) by 401.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,183 shares of the company’s stock after purchasing an additional 32,967 shares during the period. State Street Corp’s holdings in Sanofi were worth $1,972,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.35% of the company’s stock.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Earnings History for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.